We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+13.36%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.76B
AUM Growth
+$158M
Cap. Flow
+$12.9M
Cap. Flow %
0.73%
Top 10 Hldgs %
26.37%
Holding
139
New
12
Increased
27
Reduced
23
Closed
3

Top Buys

Rank Stock Value
1
ELLI
Ellie Mae Inc
ELLI
+$22.2M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.2M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$13.2M
5
FIVN icon
FIVE9
FIVN
+$12.5M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$19M
2
BLUE
bluebird bio
BLUE
+$17M
3
SPLK
Splunk Inc
SPLK
+$10.6M
4
PFPT
Proofpoint, Inc.
PFPT
+$9.51M
5
KITE
Kite Pharma, Inc.
KITE
+$8.81M

Sector Composition

Rank Sector Weight
1 Healthcare 38.21%
2 Technology 13.87%
3 Consumer Discretionary 13.68%
4 Industrials 7.76%
5 Utilities 4.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SUPN icon
76
Supernus Pharmaceuticals
SUPN
$2.65B
$5.2M 0.29%
130,000
-39,000
-23% -$1.69M
EXAS
77
DELISTED
Exact Sciences
EXAS
$4.71M 0.27%
100,000
– –
INCY icon
78
Incyte
INCY
$24.9B
$4.67M 0.26%
40,000
– –
RARE icon
79
Ultragenyx Pharmaceutical
RARE
$2.56B
$4.66M 0.26%
87,400
– –
ATHN
80
DELISTED
Athenahealth, Inc.
ATHN
$4.6M 0.26%
37,000
– –
RXDX
81
DELISTED
Ignyta, Inc.
RXDX
$4.25M 0.24%
344,000
– –
RGEN icon
82
Repligen
RGEN
$8.1B
$4.21M 0.24%
110,000
– –
ATRC icon
83
AtriCure
ATRC
$2.04B
$4.03M 0.23%
180,000
– –
ACHN
84
DELISTED
Achillion Pharmaceuticals
ACHN
$3.82M 0.22%
850,000
– –
ACRS icon
85
Aclaris Therapeutics
ACRS
$743M
$3.61M 0.2%
140,000
– –
TSRO
86
DELISTED
TESARO, Inc.
TSRO
$3.36M 0.19%
26,000
– –
REGN icon
87
Regeneron Pharmaceuticals
REGN
$76B
$3.35M 0.19%
7,500
– –
DERM
88
DELISTED
Dermira, Inc.
DERM
$3.35M 0.19%
124,000
– –
TTPH
89
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3.17M 0.18%
23,185
-6,815
-23% -$912K
MYOK
90
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$3.13M 0.18%
+73,000
New +$2.33M
IRWD icon
91
Ironwood Pharmaceuticals
IRWD
$614M
$3.03M 0.17%
229,248
– –
TCON
92
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$2.83M 0.16%
4,500
– –
NTUS
93
DELISTED
Natus Medical Inc
NTUS
$2.81M 0.16%
75,000
– –
MGNX icon
94
MacroGenics
MGNX
$240M
$2.72M 0.15%
147,000
– –
KALV
95
DELISTED
KalVista Pharmaceuticals
KALV
$2.64M 0.15%
396,000
+206,100
+109% +$1.47M
SNDX icon
96
Syndax Pharmaceuticals
SNDX
$1.73B
$2.63M 0.15%
225,000
– –
NGNE icon
97
Neurogene
NGNE
$670M
$2.48M 0.14%
8,750
– –
PBYI icon
98
Puma Biotechnology
PBYI
$402M
$2.4M 0.14%
+20,000
New +$1.86M
SEP
99
DELISTED
Spectra Engy Parters Lp
SEP
$2.22M 0.13%
50,000
-2,500
-5% -$111K
PTGX icon
100
Protagonist Therapeutics
PTGX
$8.92B
$2.21M 0.13%
125,000
– –
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Eventide Asset Management held 139 positions worth $1.76B, up 9.9% from $1.61B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management's Q3 2017 filing shows 12 new, 27 increased, 23 reduced and 3 closed positions. Its largest new stake was Ellie Mae Inc: 242,000 shares worth $19.9M. The largest sale was Loxo Oncology, Inc, an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q3 2017 buy was Ellie Mae Inc: 242,000 shares worth $19.9M.
  • Eventide Asset Management added most to Vertex Pharmaceuticals in Q3 2017, an estimated $21.9M increase.
  • Eventide Asset Management's biggest Q3 2017 reduction was Loxo Oncology, Inc, cutting an estimated $19M.
  • Eventide Asset Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $8.81M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $1.76B portfolio in Q3 2017.
  • Eventide Asset Management opened 12 new positions and closed 3 in Q3 2017.
  • Eventide Asset Management's portfolio value rose 9.9% quarter-over-quarter to $1.76B.

Based on Eventide Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.